JP6317324B2 - 神経障害を予防および処置するための方法および組成物 - Google Patents

神経障害を予防および処置するための方法および組成物 Download PDF

Info

Publication number
JP6317324B2
JP6317324B2 JP2015503653A JP2015503653A JP6317324B2 JP 6317324 B2 JP6317324 B2 JP 6317324B2 JP 2015503653 A JP2015503653 A JP 2015503653A JP 2015503653 A JP2015503653 A JP 2015503653A JP 6317324 B2 JP6317324 B2 JP 6317324B2
Authority
JP
Japan
Prior art keywords
hyperalgesia
peptide
neuropathy
acid
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015503653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512420A5 (enExample
JP2015512420A (ja
Inventor
ディー トラヴィス ウィルソン
ディー トラヴィス ウィルソン
Original Assignee
ステルス ペプチドズ インターナショナル インコーポレイテッド
ステルス ペプチドズ インターナショナル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステルス ペプチドズ インターナショナル インコーポレイテッド, ステルス ペプチドズ インターナショナル インコーポレイテッド filed Critical ステルス ペプチドズ インターナショナル インコーポレイテッド
Publication of JP2015512420A publication Critical patent/JP2015512420A/ja
Publication of JP2015512420A5 publication Critical patent/JP2015512420A5/ja
Application granted granted Critical
Publication of JP6317324B2 publication Critical patent/JP6317324B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2015503653A 2012-03-30 2013-03-29 神経障害を予防および処置するための方法および組成物 Active JP6317324B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261618428P 2012-03-30 2012-03-30
US61/618,428 2012-03-30
PCT/US2013/034647 WO2013149172A1 (en) 2012-03-30 2013-03-29 Methods and compositions for the prevention and treatment neuropathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018063574A Division JP2018123143A (ja) 2012-03-30 2018-03-29 神経障害を予防および処置するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2015512420A JP2015512420A (ja) 2015-04-27
JP2015512420A5 JP2015512420A5 (enExample) 2016-05-26
JP6317324B2 true JP6317324B2 (ja) 2018-04-25

Family

ID=49261299

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015503653A Active JP6317324B2 (ja) 2012-03-30 2013-03-29 神経障害を予防および処置するための方法および組成物
JP2018063574A Pending JP2018123143A (ja) 2012-03-30 2018-03-29 神経障害を予防および処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018063574A Pending JP2018123143A (ja) 2012-03-30 2018-03-29 神経障害を予防および処置するための方法および組成物

Country Status (8)

Country Link
US (5) US9636378B2 (enExample)
EP (3) EP3406257B1 (enExample)
JP (2) JP6317324B2 (enExample)
CN (2) CN107320712A (enExample)
AU (2) AU2013237827B2 (enExample)
CA (1) CA2869080C (enExample)
DK (1) DK2830644T3 (enExample)
WO (1) WO2013149172A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018123143A (ja) * 2012-03-30 2018-08-09 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3466439A1 (en) * 2011-12-09 2019-04-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
WO2018034901A1 (en) * 2016-08-16 2018-02-22 Stealth Biotherapeutics N-carboxyanhydride-based-scale synthesis of elamipretide
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
CN112961249B (zh) * 2021-02-25 2023-08-04 兰州大学 一类基于阿片肽和大麻肽的双功能肽及其制备方法与应用
JPWO2024253189A1 (enExample) * 2023-06-09 2024-12-12

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5913318A (ja) 1982-07-13 1984-01-24 株式会社村田製作所 電子部品の製造方法
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US6376467B1 (en) 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
ES2436011T3 (es) * 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
CN100536909C (zh) * 2003-02-04 2009-09-09 科内尔研究基金会 用于防止线粒体通透性改变的方法
RU2376028C2 (ru) * 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
CA2947330C (en) * 2005-09-16 2018-06-05 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
CA2713150C (en) * 2008-02-07 2016-01-05 Cornell University Methods for preventing or treating insulin resistance
DK2262520T3 (en) * 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
CN102573881A (zh) * 2009-03-20 2012-07-11 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
DK2464371T3 (en) * 2009-08-12 2016-06-27 Univ Cornell Methods for preventing or treating metabolic syndrome
WO2011025734A1 (en) * 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
EP2764871A1 (en) * 2009-10-05 2014-08-13 Cornell University Methods for the prevention or treatment of heart failure
WO2011082324A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
US20130190244A1 (en) * 2009-12-31 2013-07-25 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
WO2011091357A1 (en) * 2010-01-25 2011-07-28 Cornell University Aromatic-cationic peptides and uses of same
EP3511012A1 (en) * 2010-02-26 2019-07-17 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2547352A4 (en) * 2010-03-15 2013-10-09 Stealth Peptides Int Inc COMBINATION THERAPIES USING CYCLOSPORINE AND AROMATIC CATIONIC PEPTIDES
JP6319738B2 (ja) * 2010-07-09 2018-05-09 ステルス ペプチドズ インターナショナル インコーポレイテッド 虚血／再灌流障害に続くノーリフローの予防又は処置方法
US20120083452A1 (en) * 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
KR101351432B1 (ko) 2011-12-27 2014-01-15 에스케이씨 주식회사 초미세 발포 폴리우레탄 탄성체의 제조방법
JP6317324B2 (ja) * 2012-03-30 2018-04-25 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018123143A (ja) * 2012-03-30 2018-08-09 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物
US11998585B2 (en) 2012-03-30 2024-06-04 Stealth Biotherapeutics Inc. Methods and compositions for increasing the dose of a chemotherapeutic agent

Also Published As

Publication number Publication date
AU2017265013B2 (en) 2019-04-18
US20170340695A1 (en) 2017-11-30
HK1206266A1 (en) 2016-01-08
AU2017265013A1 (en) 2017-12-07
EP3406257A1 (en) 2018-11-28
US20220296672A1 (en) 2022-09-22
EP3170506B1 (en) 2018-05-16
CN104271146A (zh) 2015-01-07
DK2830644T3 (en) 2017-02-27
CA2869080C (en) 2020-09-01
WO2013149172A1 (en) 2013-10-03
US9636378B2 (en) 2017-05-02
US20200397850A1 (en) 2020-12-24
US10279008B2 (en) 2019-05-07
AU2013237827B2 (en) 2017-12-14
CN107320712A (zh) 2017-11-07
AU2017265013B9 (en) 2019-05-02
CA2869080A1 (en) 2013-10-03
EP2830644B1 (en) 2016-11-16
EP2830644A1 (en) 2015-02-04
JP2018123143A (ja) 2018-08-09
AU2013237827A1 (en) 2014-10-16
EP3406257B1 (en) 2020-04-22
US20150087595A1 (en) 2015-03-26
JP2015512420A (ja) 2015-04-27
EP3170506A1 (en) 2017-05-24
US11998585B2 (en) 2024-06-04
US10646539B2 (en) 2020-05-12
US20190343913A1 (en) 2019-11-14
EP2830644A4 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
US11998585B2 (en) Methods and compositions for increasing the dose of a chemotherapeutic agent
US20230201299A1 (en) Methods for the prevention and treatment of burn injuries and secondary complications
JP2019214580A (ja) ミトコンドリア疾患の治療のための方法
CN102791280A (zh) 用于预防或治疗血管阻塞损伤的方法
EP3120860A1 (en) Methods for the prevention or treatment of cardiac fibrosis
CN106163537A (zh) 心磷脂靶向肽抑制β‑淀粉样蛋白寡聚物毒性
HK1238151A1 (en) Methods and compositions for the prevention and treatment neuropathy
HK1238151B (en) Methods and compositions for the prevention and treatment neuropathy
HK1261709B (en) Methods and compositions for the prevention and treatment neuropathy
HK1261709A1 (en) Methods and compositions for the prevention and treatment neuropathy
US20170007663A1 (en) Methods and compositions for treating and preventing cognitive dysfunction
HK1206266B (en) Methods and compositions for the prevention and treatment neuropathy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180329

R150 Certificate of patent or registration of utility model

Ref document number: 6317324

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250